KRH-3955
KRH-3955 is a CXCR4 antagonist with good bioavailability and potent anti-HIV-1 activity. KRH-3955 can effectively inhibit the replication of X4 HIV-1, including clinical isolates from different donors. KRH-3955 also shows activity against recombinant X4 HIV-1 containing reverse transcriptase, protease and tyrosinase resistance mutations. KRH-3955 can inhibit the binding of SDF-1alpha to CXCR4 and calcium ion signaling through this receptor. KRH-3955 inhibits the binding of an antibody against CXCR4 to CXCR4, showing a potent antagonistic effect on CXCR4. KRH-3955 shows an oral bioavailability of 25.6% in rats and can inhibit the replication of X4 HIV-1 in vivo[1].
Product Specifications
CAS Number
1097732-62-1
UNSPSC
12352005
Target
HIV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/krh-3955.html
Smiles
CCCN(CCCCN(C)CC1=CC=C(C=C1)CN(CC2=NC=CN2C)CC3=NC=CN3)CCC.O=C([C@@H]([C@H](C(O)=O)O)O)O.O=C([C@@H]([C@H](C(O)=O)O)O)O.O=C([C@@H]([C@H](C(O)=O)O)O)O
Molecular Formula
C40H63N7O18
Molecular Weight
929.96
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human Lambda Light Chain (B-Cell Marker) (rLLC/3777), CF647 conjugate, 0.1mg/mL
P63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF594 conjugate, 0.1mg/mL
TLE1 (Synovial Sarcoma Marker) (TLE1/2051), Biotin conjugate, 0.1mg/mL
Neuro D4 (DPF1) (NM_001135155) Human Over-expression Lysate
